Home › Funds › Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. › CYTK

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. position in CYTK

CYTOKINETICS INC · Health Care

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. reported holding 660,310 shares of CYTK (CYTOKINETICS INC) in its Q3 2026 13F filing — a position valued at US$43.5M, representing 2.09% of its reported portfolio and ranking #20 among its reported holdings. Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. has disclosed CYTK holdings in 10 of the last 12 reported quarters, going back to Q4 2023.

Latest position (Q3 2026)660.31K sh
Reported value held$43.52M
Portfolio Weight2.09%
First reportedQ4 2023
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A.'s CYTK position evolved

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. first disclosed a stake in CYTK in Q4 2023 at 344,484 shares (US$28.8M). The position peaked in Q3 2025 at 1,192,484 shares, worth US$65.5M. Across 10 filings, Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. increased the stake 3 time(s), trimmed it 3 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 660,310 shares valued at US$43.5M. Notable position changes include a 51% trim in Q1 2025 (shares fell 18% over the following quarter), a 571% increase in Q2 2025 (shares rose 66% over the following quarter), a 37% trim in Q4 2025 (shares rose 4% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 344.48K $28.76M New
Q1 2024 461.02K $32.32M Add
Q4 2024 329.14K $15.48M New
Q1 2025 161.28K $6.48M Reduce
Q2 2025 1.08M $35.77M Add
Q3 2025 1.19M $65.54M Add
Q4 2025 747.98K $47.53M Reduce
Q1 2026 660.31K $43.52M Reduce
Q2 2026 660.31K $56.25M Hold
Q3 2026 660.31K $43.52M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CYTK and 13F data

CYTK (CYTOKINETICS INC) is a Health Care company. 44 other funds we track also report a position in CYTK — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.59B), Avoro Capital Advisors LLC (US$425.9M), RTW INVESTMENTS, LP (US$243.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CYTK

All CYTK fund holders →

FAQ

How long has Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. held CYTK?

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. has disclosed CYTK holdings in 10 of the last 12 reported quarters, going back to Q4 2023.

What is Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A.'s current position in CYTK?

As of Q3 2026, Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. holds 660.31K shares of CYTK (CYTOKINETICS INC), valued at $43.52M, representing 2.09% of its reported portfolio and ranking #20.

Has Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. been buying or selling CYTK?

In the latest 13F filing (Q3 2026), Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. held unchanged its position in CYTK. The position peaked in Q3 2025 at 1.19M shares.

Which other funds hold CYTK?

Other major institutional holders of CYTK include T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, RTW INVESTMENTS, LP, among 44 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.